Group One Trading
MACK

Group One Trading’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Group One Trading’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-22,100
Closed -$326K – 7774
2024
Q1 		$326K Buy
22,100
+19,700
+821% +$277K ﹤0.01% 3145
2023
Q4 		$32.2K Sell
2,400
-15,000
-86% -$190K ﹤0.01% 5387
2023
Q3 		$215K Sell
17,400
-8,800
-34% -$107K ﹤0.01% 3751
2023
Q2 		$322K Sell
26,200
-80,800
-76% -$1.01M ﹤0.01% 3474
2023
Q1 		$1.32M Buy
107,000
+10,700
+11% +$126K ﹤0.01% 1899
2022
Q4 		$1.1M Buy
96,300
+96,100
+48,050% +$791K ﹤0.01% 2327
2022
Q3 		$1K Sell
200
-1,700
-89% -$7.85K ﹤0.01% 7437
2022
Q2 		$11K Sell
1,900
-1,700
-47% -$9.59K ﹤0.01% 6737
2022
Q1 		$23K Buy
+3,600
New +$20.2K ﹤0.01% 6684
2021
Q4 		– Sell
-1,000
Closed -$5K – 9248
2021
Q3 		$5K Sell
1,000
-600
-38% -$3.13K ﹤0.01% 7788
2021
Q2 		$10K Sell
1,600
-36,100
-96% -$238K ﹤0.01% 7544
2021
Q1 		$237K Sell
37,700
-12,600
-25% -$90.1K ﹤0.01% 4848
2020
Q4 		$347K Sell
50,300
-25,800
-34% -$127K ﹤0.01% 3600
2020
Q3 		$304K Sell
76,100
-11,200
-13% -$41.1K ﹤0.01% 3311
2020
Q2 		$291K Buy
87,300
+80,300
+1,147% +$274K ﹤0.01% 3077
2020
Q1 		$15K Buy
7,000
+4,500
+180% +$13.2K ﹤0.01% 4403
2019
Q4 		$8K Sell
2,500
-5,200
-68% -$20.8K ﹤0.01% 4672
2019
Q3 		$35K Buy
7,700
+1,091
+17% +$5.45K ﹤0.01% 4156
2019
Q2 		$31K Buy
+6,609
New +$31.3K ﹤0.01% 4015
2018
Q4 		– Sell
-2,542
Closed -$11K – 5900
2018
Q3 		$11K Sell
2,542
-508
-17% -$2.14K ﹤0.01% 4641
2018
Q2 		$12K Buy
+3,050
New +$20.3K ﹤0.01% 4572
2017
Q4 		– Sell
-1,779
Closed -$20K – 5617
2017
Q3 		$20K Sell
1,779
-712
-29% -$7.49K ﹤0.01% 4078
2017
Q2 		$24K Sell
2,491
-2,479
-50% -$50.6K ﹤0.01% 3884
2017
Q1 		$120K Buy
4,970
+2,415
+95% +$60.4K ﹤0.01% 2857
2016
Q4 		$82K Buy
2,555
+2,542
+19,554% +$108K ﹤0.01% 2963
2016
Q3 		$1K Sell
13
-1,207
-99% -$50.1K ﹤0.01% 4479
2016
Q2 		$52K Sell
1,220
-12,113
-91% -$660K ﹤0.01% 3288
2016
Q1 		$878K Buy
13,333
+8,300
+165% +$433K 0.01% 1275
2015
Q4 		$313K Sell
5,033
-9,113
-64% -$641K ﹤0.01% 2169
2015
Q3 		$947K Sell
14,146
-432
-3% -$35.3K 0.01% 1288
2015
Q2 		$1.42M Buy
14,578
+3,380
+30% +$322K 0.02% 960
2015
Q1 		$1.05M Buy
11,198
+4,741
+73% +$403K 0.02% 1045
2014
Q4 		$574K Sell
6,457
-18,544
-74% -$1.35M 0.01% 1455
2014
Q3 		$1.73M Sell
25,001
-9,926
-28% -$530K 0.03% 773
2014
Q2 		$2M Buy
34,927
+32,309
+1,234% +$1.64M 0.03% 696
2014
Q1 		$104K Sell
2,618
-2,008
-43% -$85.9K ﹤0.01% 3039
2013
Q4 		$194K Buy
4,626
+3,571
+338% +$104K ﹤0.01% 2464
2013
Q3 		$32K Sell
1,055
-3,381
-76% -$118K ﹤0.01% 3888
2013
Q2 		$235K Buy
+4,436
New +$194K 0.01% 2031

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Group One Trading's MACK Position: Q1 2024 in Review

Group One Trading sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2024, closing a stake of 236 shares — an estimated $3.32K sold.

Group One Trading first reported a position in MACK in Q3 2013 and held it in 26 quarters. The position peaked at $1.2M in Q1 2014. 70 funds tracked by Wall St. Rank hold MACK as of Q1 2024.

  • Group One Trading reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Group One Trading sold 236 Merrimack Pharmaceuticals, Inc. shares in Q1 2024, an estimated $3.32K.
  • Group One Trading first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 26 quarters.
  • Group One Trading's Merrimack Pharmaceuticals, Inc. position peaked at $1.2M in Q1 2014.
  • 70 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2024.

Based on Group One Trading's 13F filing for Q1 2024, filed 10 May 2024.